BIOLASE (NASDAQ: BIOL) and Quidel (NASDAQ:QDEL) are both small-cap advanced medical equipment & technology – nec companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.
Insider and Institutional Ownership
38.8% of BIOLASE shares are held by institutional investors. Comparatively, 92.7% of Quidel shares are held by institutional investors. 7.1% of BIOLASE shares are held by company insiders. Comparatively, 22.0% of Quidel shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This table compares BIOLASE and Quidel’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares BIOLASE and Quidel’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BIOLASE||$51.81 million||0.76||-$15.37 million||($0.33)||-1.58|
|Quidel||$191.60 million||8.25||-$13.80 million||($0.15)||-309.78|
Quidel has higher revenue and earnings than BIOLASE. Quidel is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings and price targets for BIOLASE and Quidel, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BIOLASE presently has a consensus price target of $2.50, indicating a potential upside of 380.77%. Quidel has a consensus price target of $50.00, indicating a potential upside of 7.60%. Given BIOLASE’s higher probable upside, analysts plainly believe BIOLASE is more favorable than Quidel.
Risk & Volatility
BIOLASE has a beta of 2.31, indicating that its stock price is 131% more volatile than the S&P 500. Comparatively, Quidel has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500.
Quidel beats BIOLASE on 10 of the 13 factors compared between the two stocks.
BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. Its diagnostic solutions aid in the detection and diagnosis of critical diseases and other medical conditions, including infectious diseases, women’s health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. The Company provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, MicroVue, FreshCells, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Quidel Molecular, Amplivue, Lyra and Thyretain.
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.